392721-37-8
基本信息
N-(4-氯-3-(三氟甲基)苯基)-3-氧代丁酰胺
Fasentin NEW
Fasentin >=98% (HPLC)
Fasentin - CAS 392721-37-8 - Calbiochem
N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide
物理化学性质
| 储存条件 | room temp |
| 溶解度 | 二甲基亚砜：>10mg/mL |
| 形态 | 粉末 |
| 颜色 | 白色至灰白色 |
| 稳定性 | DMSO中的溶液可在-20°下稳定储存3个月。 |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302 |
| 防范说明 | P264-P270-P301+P312-P330-P501 |
| 危险品标志 | Xn |
| 危险类别码 | 22 |
| WGK Germany | 3 |
N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-101849 | N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide Fasentin | 392721-37-8 | 5mg | 700元 |
| 2024/04/30 | HY-101849 | N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide Fasentin | 392721-37-8 | 10mM * 1mLin DMSO | 770元 |
| 2024/04/30 | HY-101849 | N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide Fasentin | 392721-37-8 | 10mg | 1100元 |
常见问题列表
|
GLUT4 68 μM (IC 50 ) |
GLUT1
|
Fasentin (0.1-1000 μM; 72 hours) inhibits endothelial, tumour and fibroblast cell growth without inducing cell death.
Fasentin (25-100 μM; 16-24 hours) induces a cell cycle arrest in G0/G1 phase and reduces the cell number in S phase in a dose-dependent manner.
Fasentin (50 μM; 16 hours) alters expression of genes associated with glucose deprivation such as AspSyn and PCK-2.
Fasentin (15, 30, 80 μM; pretreatment 1 hour) induces glucose deprivation, partially blocks glucose uptake in PPC-1, DU145, and U937 cells.
Fasentin (100 μM; 16 hours) does not affect the migratory capability of endothelial cells.
Fasentin (25-100 μM; 16 hours) lowers levels of phospho-ERK in HMECs, indicating a partial inhibition on the ERK signalling pathway, even though the effect is not statistically significant. Fasentin does not inhibit the tyrosine kinase activity of VEGFR2.
Fasentin interacts with a unique site in the intracellular channel of GLUT1.
Cell Viability Assay
| Cell Line: | Three types of endothelial cells ECs (HMEC, human microvascular endothelial cells; HUVEC, human umbilical vein endothelial cells; and BAEC, bovine aortic endothelial cells), three human tumour cell lines (MDA-MB-231 and MCF7 breast carcinoma cells, and HeLa cervix adenocarcinoma cells), and human gingival fibroblasts (HGF) |
| Concentration: | 0.1, 1, 10, 100, 1000 μM |
| Incubation Time: | 72 hours |
| Result: | Inhibited endothelial, tumour and fibroblast cell growth (IC 50 =26.3-111.2 μM) without inducing cell death. |
Cell Cycle Analysis
| Cell Line: | HMECs |
| Concentration: | 25, 50, 100 μM |
| Incubation Time: | 16, 24 hours |
| Result: |
Induced a cell cycle arrest in G0/G1 phase and reduced the cell number in S phase in a dose-dependent manner.
Did not increase the subG1 population. |
RT-PCR
| Cell Line: | PPC-1 cells [2] |
| Concentration: | 50 μM |
| Incubation Time: | 16 hours |
| Result: | Altered expression of genes associated with glucose deprivation such as AspSyn and PCK-2 not FLIP mRNA expression. |